Login / Signup

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.

May Yee ChoiAnn Elaine ClarkeMurray B UrowitzJohn HanlyYvan St-PierreCaroline GordonSang-Cheol BaeJuanita Romero-DiazJorge Sanchez-GuerreroSasha BernatskyDaniel J WallaceDavid Alan IsenbergAnisur RahmanJoan T MerrillPaul R FortinDafna D GladmanIan N BruceMichelle A PetriEllen M GinzlerMary Anne DooleyRosalind Ramsey-GoldmanSusan ManziAndreas JönsenGraciela S AlarconRonald F Van VollenhovenCynthia AranowMeggan MackayGuillermo Ruiz-IrastorzaSam LimMurat InançKen KalunianSøren JacobsenChristine PeschkenDiane L KamenAnca AskanaseJill P BuyonKaren H CostenbaderMarvin J Fritzler
Published in: Annals of the rheumatic diseases (2022)
In recent-onset SLE, three ANA assays demonstrated commutability with a high proportion of positivity and titres or AU. However, over 5 years follow-up, there was modest variation in ANA assay performance. In clinical situations where the SLE diagnosis is being considered, a negative test by either the ELISA or HEp-2 IFA may require reflex testing.
Keyphrases
  • systemic lupus erythematosus
  • disease activity
  • high throughput
  • rheumatoid arthritis
  • primary care
  • sensitive detection
  • reduced graphene oxide
  • gold nanoparticles
  • monoclonal antibody
  • quantum dots
  • drug induced